Moreover, EHMT2 can mediate HFD-induced obesity, hepatic steatosis, and hepatic insulin resistance [24, 25], emerging as a therapeutic candidate for obesity and associated diseases. This evidence concerns the gene EHMT2 and obesity disorder.